Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

The following is a summary of “Cost–consequence analysis of early vs. delayed natalizumab use in highly active ...

Regardless of sociodemographic or clinical characteristics, children with food allergy face a significant psychosocial burden ...

Teva Pharmaceuticals agreed to pay $450m over claims it used charities to boost sales of the multiple sclerosis drug Copaxone (glatiramer acetate) in October 2024.

The US agency maintains that Glatiramer acetate is an approved medicine to treat patients with relapsing forms of MS. (Image Credits: Reuters) The U.S. Food and Drug Administration (FDA ...

The US Food and Drug Administration (FDA) is adding the risk of anaphylaxis to a new boxed warning of glatiramer acetate, a medicine for multiple sclerosis (MS). The agency issued the warning about ...

The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of multiple sclerosis drugs including Teva's Copaxone. The health ...

Amid a deluge of executive actions, the Trump administration has directed federal health agencies to pause external ...

Already Wednesday morning, the FDA sent out a communication about a safety warning added to the multiple sclerosis drug glatiramer acetate, which goes by brand names including Copaxone ...